<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03140722</url>
  </required_header>
  <id_info>
    <org_study_id>AKB-6548-CI-0018</org_study_id>
    <nct_id>NCT03140722</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Who Are Hyporesponsive to Erythropoiesis Stimulating Agents</brief_title>
  <official_title>Phase 2, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Treatment of Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Who Are Hyporesponsive to Erythropoiesis Stimulating Agents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Akebia Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Akebia Therapeutics</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2, randomized, open-label study to evaluate vadadustat versus epoetin alfa
      for the treatment of anemia in subjects with DD-CKD who are hyporesponsive to ESAs.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Revised study design.
  </why_stopped>
  <start_date type="Actual">May 23, 2017</start_date>
  <completion_date type="Actual">April 11, 2018</completion_date>
  <primary_completion_date type="Actual">March 21, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the change in Hb from baseline over time</measure>
    <time_frame>20 weeks</time_frame>
    <description>Change in Hb during the treatment time period will be evaluated</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects demonstrating incremental increases in Hb from baseline over time</measure>
    <time_frame>20 weeks</time_frame>
    <description>Proportion of subjects demonstrating incremental increases in Hb during the treatment period will be evaluated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects receiving epoetin alfa rescue</measure>
    <time_frame>20 weeks</time_frame>
    <description>Subjects receiving epoetin alfa rescue will be evaluated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects receiving RBC transfusion</measure>
    <time_frame>20 weeks</time_frame>
    <description>Subjects receiving RBC transfusion will be evaluated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with Hb values within the target range</measure>
    <time_frame>20 weeks</time_frame>
    <description>Hemoglobin values within the target range will be evaluated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>20 weeks</time_frame>
    <description>Adverse Events (AEs) and Serious Adverse Events (SAEs) will be evaluated</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Anemia</condition>
  <condition>Dialysis-Dependent Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>vadadustat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vadadustat daily oral dose, adjustable based on Hb level</description>
  </arm_group>
  <arm_group>
    <arm_group_label>epoetin alfa</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Epoetin alfa, dose adjustable based on Hb level, as clinically indicated throughout the study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vadadustat</intervention_name>
    <description>vadadustat</description>
    <arm_group_label>vadadustat</arm_group_label>
    <other_name>AKB-6548</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>epoetin alfa</intervention_name>
    <description>epoetin alfa</description>
    <arm_group_label>epoetin alfa</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female subjects ≥18 years of age

          -  Receiving chronic maintenance hemodialysis for end-stage kidney disease

          -  Currently receiving epoetin alfa for anemia at a dose of ≥7700 units per dialysis
             treatment session or ≥23100 units per week

          -  Hb between 8.5 and 10.0 g/dL during screening

        Exclusion Criteria:

          -  Anemia due to a cause other than CKD or presence of active bleeding or recent blood
             loss

          -  Sickle cell disease, myelodysplastic syndromes, bone marrow fibrosis, hematologic
             malignancy, myeloma, hemolytic anemia, thalassemia, or pure red cell aplasia

          -  Red blood cell transfusion within 4 weeks prior to or during screening

          -  Anticipated to recover adequate kidney function to no longer require hemodialysis
             during study participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Elk Grove</city>
        <state>California</state>
        <zip>95758</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Encino</city>
        <state>California</state>
        <zip>91316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Escondido</city>
        <state>California</state>
        <zip>92025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lynwood</city>
        <state>California</state>
        <zip>90262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Luis Obispo</city>
        <state>California</state>
        <zip>93401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Waterbury</city>
        <state>Connecticut</state>
        <zip>06708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33183</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Statesboro</city>
        <state>Georgia</state>
        <zip>30458</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10473</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79915</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77070</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <zip>23605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2017</study_first_submitted>
  <study_first_submitted_qc>May 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 4, 2017</study_first_posted>
  <last_update_submitted>April 23, 2018</last_update_submitted>
  <last_update_submitted_qc>April 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>anemia</keyword>
  <keyword>kidney</keyword>
  <keyword>dialysis-dependent chronic kidney disease</keyword>
  <keyword>CKD</keyword>
  <keyword>DD-CKD</keyword>
  <keyword>renal</keyword>
  <keyword>vadadustat</keyword>
  <keyword>AKB-6548</keyword>
  <keyword>hypoxia-inducible factor</keyword>
  <keyword>HIF</keyword>
  <keyword>hypoxia-inducible factor prolyl-hydroxylase inhibitor</keyword>
  <keyword>HIF-PHI</keyword>
  <keyword>hyporesponder</keyword>
  <keyword>hyporesponsive</keyword>
  <keyword>epoetin alfa</keyword>
  <keyword>hemoglobin</keyword>
  <keyword>erythropoiesis stimulating agent</keyword>
  <keyword>ESA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
    <mesh_term>Hematinics</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

